Multiple-ascending-dose phase 1 clinical study of the safety, tolerability, and pharmacokinetics of CrS3123, a narrow-spectrum agent with minimal disruption of normal gut microbiota

Barbara K. Lomeli, Hal Galbraith, Jared Schettler, George A. Saviolakis, Wael El-Amin, Blaire Osborn, Jacques Ravel, Keith Hazleton, Catherine A. Lozupone, Ronald J. Evans, Stacie J. Bell, Urs A. Ochsner, Thale C. Jarvis, Shahida Baqar, Nebojsa Janjic

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Multiple-ascending-dose phase 1 clinical study of the safety, tolerability, and pharmacokinetics of CrS3123, a narrow-spectrum agent with minimal disruption of normal gut microbiota'. Together they form a unique fingerprint.

Medicine & Life Sciences